TP53 and neoplasm: Mutant TP53 can be restored by targeting Cys124 and Cys277 with methylene quinuclidinone converted from APR-246 [50], and eprenetapopt (APR-246) inhibits esophageal cellular proliferation and xenograft tumor growth by inducing ferroptosis, inhibiting NFS1 cysteine desulfurase, and synergizing with dietary serine and glycine restriction [51].